| 2026-08-15 | AICAR: Identity, Evidence and Substance Identifiers |
| 2026-08-15 | Amycretin: Zenagamtide Identity, Trials and Status |
| 2026-08-15 | AOD-9604: LAT8881 Identity, Human Trials and Status |
| 2026-08-17 | Anamorelin: Trial Results, Japan Approval and EU Status |
| 2026-08-17 | Weight loss injection: retatrutide, Mounjaro, Wegovy |
| 2026-08-19 | BPC-157/TB500 recovery: human studies and vial tests |
| 2026-08-20 | Peptide injection site reaction: infection and vial evidence |
| 2026-08-20 | Research peptides: what tests found inside the vial |
| 2026-08-20 | Injection site reaction when to worry - emergency numbers |
| 2026-08-20 | Tanning injections: melanotan II studies and vial tests |
| 2026-08-21 | CJC 1295: Human Studies, Side Effects and Vial Tests |
| 2026-08-21 | Fake Ozempic: What Product Tests and Case Reports Found |
| 2026-08-21 | Retatrutide Side Effects and Trial Results in 2026 |
| 2026-08-21 | Side effects of TB-500: human data, FDA and vial tests |
| 2026-08-21 | Certificate of analysis meaning: what a COA proves |
| 2026-08-21 | Peptide Reconstitution Math: mg, mL and Syringe Units |
| 2026-08-21 | For Research Use Only Labels Under EU Medicines Law |
| 2026-08-21 | Medical Confidentiality in Sweden and Germany Explained |
| 2026-08-22 | About VialFacts: Peptide Evidence, Sources and Method |
| 2026-08-22 | AOD 9604 Human Trials, Animal Results and Vial Evidence |
| 2026-08-22 | Ipamorelin Human Studies, Side Effects and Vial Tests |
| 2026-08-22 | Melanotan 2 Human Tanning Results, Side Effects and Vials |
| 2026-08-22 | VialFacts Method: Checking Peptide Claims and Sources |
| 2026-08-22 | VialFacts Editorial Policy: Evidence, Sources and Readers |
| 2026-08-22 | What Are Peptides? Definition, Peptide Bonds and Evidence |
| 2026-08-24 | Peptide Guide: Eight Compounds, Studies and Vial Tests |
| 2026-08-24 | BRP Peptide: Current Identity, Animal Findings and Status |
| 2026-08-24 | Dihexa: Rat Memory Results, Human Evidence and EU Status |
| 2026-08-24 | DSIP Peptide (Emideltide): Human Trials and EU Status |
| 2026-08-24 | Eloralintide: Phase 2 Weight Loss, Safety and EU Status |
| 2026-08-24 | Epithalon (Epitalon): Human Study Results and EU Status |
| 2026-08-24 | Follistatin 344: Human Gene Therapy and Product Tests |
| 2026-08-24 | GHK-Cu (Copper Peptide): Topical Trial and Vial Data |
| 2026-08-24 | GHRP-2-Gly: Identity, Seized Vials and Evidence Gaps |
| 2026-08-24 | GHRP-2 (Pralmorelin): Human GH and Appetite Results |
| 2026-08-24 | GHRP-6-Gly: Identity, Seized Products and Evidence Gap |
| 2026-08-24 | GHRP-6: Human GH Results, Half-Life and Identifiers |
| 2026-08-24 | Hexarelin (Examorelin): Human GH and Cardiac Results |
| 2026-08-24 | HGH Fragment 176-191: Human Evidence and AOD Difference |
| 2026-08-24 | KPV Peptide: Mouse Colitis Results and Human Evidence |
| 2026-08-24 | Ghrelin (Lenomorelin) 2026: Human Trials and EU Status |
| 2026-08-24 | Macimorelin Test: Phase 3 Accuracy and EU Authorisation |
| 2026-08-24 | Are Peptides Safe? Side Effects, Purity and Vial Tests |
| 2026-08-25 | LL-37 (Ropocamptide): Human Trials and EU Status 2026 |
| 2026-08-25 | Mazdutide: Phase 3 Weight-Loss Results and EU Status |
| 2026-08-25 | MK-677 (Ibutamoren): Human Results and EU Trial Status |
| 2026-08-25 | MOTS-c: Human Evidence, Animal Results and EU Status |
| 2026-08-25 | PEG-MGF Evidence, Human Data and Regulatory Status |
| 2026-08-25 | Pemvidutide Human Results, Sponsors and EU Status 2026 |
| 2026-08-25 | Petrelintide Human Results, Sponsors and EU Trials |
| 2026-08-25 | PT-141: US Approval, Phase 3 Results and Trial Evidence |
| 2026-08-25 | Selank: Human Studies, FDA Record and Evidence Gaps |
| 2026-08-25 | Semax: Human Studies, FDA Review and Evidence Gaps |
| 2026-08-25 | Sermorelin: Human Trial, Approval History and Evidence |
| 2026-08-25 | Survodutide: Phase 3 Weight Loss and MASH Trial Results |
| 2026-08-26 | VialFacts Changelog: Claim Dates and Verified Changes |
| 2026-08-26 | Alexamorelin: Human GH Response, Identity and Status |
| 2026-08-26 | LongR3-IGF-1: Animal Findings, Identity and Status |
| 2026-08-26 | Mecasermin: Increlex Growth Results, Approval and Safety |
| 2026-08-26 | Orforglipron: Phase 3 Weight Loss, Safety and Status |
| 2026-08-26 | Somatorelin: Human Studies, GHRH Identity and Status |
| 2026-08-26 | Stamulumab: MYO-029 Trial Results, Identity and Status |
| 2026-08-26 | Tabimorelin: Human Studies, GH Response and Status |
| 2026-08-26 | Tesofensine: Phase 2 Weight Loss, Safety and Status |
| 2026-08-26 | Thymosin Alpha 1: Trial Results, Status and Safety |
| 2026-08-26 | VK2735: Phase 2 Weight Loss, Safety and Trial Status |
| 2026-08-27 | Peptide Research, Vial Tests and User Reports | VialFacts |
| 2026-08-28 | Contact VialFacts: Corrections and Privacy Questions |
| 2026-08-28 | VialFacts Corrections: The Public Record After Launch |
| 2026-08-29 | VialFacts Privacy: Analytics, Cookies and Contact Email |
| 2026-08-29 | BPC 157 Peptides: Human Reports, Study Doses and Vials |
| 2026-08-30 | CJC-1295 Peptide: GH Trial Data, DAC and Vial Tests |
| 2026-08-30 | CJC 1295/Ipamorelin Peptide: Trials and Vial Tests |
| 2026-08-30 | Melanotan 2 Peptide: Tanning, ED Results and Vials |
| 2026-08-30 | TB 500 Peptide: Human Evidence, Rat Results and Vials |
| 2026-09-02 | Retatrutide Peptide: Trial Results, Doses and Vial Tests |
| 2026-09-02 | Tesamorelin Dosage per Day: Trials and Egrifta Facts |
| 2026-09-02 | Peptide List: 52 Compounds by Evidence and EU Status |
| 2026-09-05 | Mod GRF 1 29 and Ipamorelin: Evidence and Doses 2026 |
| 2026-09-06 | Cagrilintide: Weight-Loss Results, Study Doses and Safety |
| 2026-09-06 | CT-388 (Enicepatide): Human Results, Doses and Status |